Repositioning Candidate Details

Candidate ID: R1587
Source ID: DB15890
Source Type: investigational
Compound Type: biotech
Compound Name: RAPA-501-Allo
Synonyms: --
Molecular Formula: --
SMILES: --
DrugBank Description: RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.
CAS Number: --
Molecular Weight:
DrugBank Indication: --
DrugBank Pharmacology: --
DrugBank MoA: The hybrid TREG and Th2 phenotype of these cells inhibits the inflammatory pathways of COVID-19 through modulation of cytokines and chemokines and cross-regulation of Th1 and Th17 populations. This therapy also has been seen to mediate protection on lung alveolar tissue. The immunomodulation that occurs is in a T-cell receptor independent manner. Currently, RAPA-501-ALLO is being investigated against COVID-19.
Targets: --
Inclusion Criteria: Therapeutic strategy associated